Figure 1.
Study design involving patients with non‐small‐cell lung cancer (NSCLC) with epidermal growth factor receptor‐activating and T790M mutations treated with ASP8273. Phase I, dose escalation; phase II, dose expansion
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.